Table 4. Antitumour activity.
Aflibercept, 4 mg kg−1, n=6 | Aflibercept, 5 mg kg−1, n=7 | Aflibercept, 6 mg kg−1, n=17 | All patients, n=30 | |
---|---|---|---|---|
Best overall response, n (%) | ||||
Partial response | 1 (16.7) | 0 | 4 (23.5) | 5 (16.7) |
Stable disease | 4 (66.7) | 7 (100.0) | 7 (41.2) | 18 (60.0) |
Progressive disease | 0 | 0 | 6 (35.3) | 6 (20.0) |
Not evaluable | 1 (16.7) | 0 | 0 | 1 (3.3) |
Patients with stable disease for >3 months, n (%) | 3 (50.0) | 3 (42.9) | 4 (23.5) | 10 (33.3) |